The Children’s Cancer Therapy Development Institute was created with one aim: to make childhood cancer universally survivable, regardless of diagnosis.
For many forms of childhood cancer, we’ve seen little to no advancement in treatment options for over thirty years.
There are new discoveries made in research labs, but sadly they are rarely if ever translated into new treatments for children. The process of turning a new scientific discovery into a new treatment is tedious, time-consuming, and rarely generates big profits. Kids wait for cures in hospital beds while potential discoveries lie dormant in scientific journals. Today we still have childhood cancers without any effective treatments upon diagnosis or relapse.
One in every 5 children has one of these incurable cancers that even 40 years of ongoing research doesn’t address. To overcome this stalemate, cc-TDI is embarking upon a bold scientific course of discovery to create more effective clinical trials for those childhood cancers that are most in need of treatments to save kids’ lives.
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Biologists and bio-medical engineers work closely on teams to identify targets on cancer cells and determine how to safely deliver effective treatments. By proving these methods in the laboratory, we can deliver smart, hope-filled discoveries to be prioritized in clinical trials for kids. Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.
Our mission is to translate scientific discovery into clinical trials by understanding and proving new disease-specific treatment options for children with cancer.
This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005. cc-TDI now fills this crucially needed role created as a result of the ever-changing climate of federal funding for childhood cancer research.
In another win for kids fighting cancer, cc-TDI sees first hand in 3 examples that performed rigorous pre-clinical testing brings important partners to the childhood cancer mission: we find pharmaceutical companies are more willing to team up and provide drugs for free to clinical trials because cc-TDI has eliminated a lot of risk from the clinical trial process. With your help, our innovative team will change the lives of children fighting cancer today and bring hope for the children who will fight tomorrow.
The families are those to whom we are primarily accountable.